You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Kyowa Kirin’s Crysvita wins EU approval for expanded XLH population

Japanese pharma Kyowa Kirin has been granted approval from the European Commission for Crysvita in older adolescents and adults with X-linked hypophosphataemia (XLH).